Abiopharma

Adicet Bio Inc (ACET) Announces Clinical Trial Update Adicet Bio Inc (ACET) provided an update on its clinical development programs. Clinical Development Highlights:

• Diseases/Conditions: cancer
• Clinical Stage: pivotal study, Phase 1
• Update Type: Trial Timeline Adjustment
• Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
• Collaboration: NHL
• Updated Timeline: first half of 2023 Company
  • targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at www.adicetbio.com. Available Information Adicet announces material information to the public about the Company, its product candidates and clinical trials, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (SEC), press releases, public conference calls, webcasts, the investor relations section of the Company website at investor.adicetbio.com and the Company’s Twitter account (@AdicetBio), in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statements This press release contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995